bakakinkorypon.blogspot.com
Dr. Frincke was also elected to the company'es board of directors. Dr. Frincke joined Hollis-Edej as Vice President, Research and Development in was promoted to Executive Vice Presidenin 1999, and to Chief Scientific Officer in 2001. Dr. Frinckse joined Hollis-Eden from Prolinx, where he served as Vice President, Therapeutics Research and Developmen from 1995to 1997. Durinyg his 28 years in the biotechnologhy industry, Dr. Frincke has managed major development programzsincluding drugs, biologicals, and cellulaer and gene therapy products aimed at the treatmen of cancer, infectious diseasesa and organ transplantation. Since joininvg the biotechnology industry, Dr.
Frinckr has held vice research and development positions in top tier biotechnology companieseincluding Hybritech/Eli Lilly and SyStemix Inc. (acquired by In various capacities, he has been responsiblde for all aspects of pharmaceutical development including earluy stageresearch programs, product evaluation, pharmacology, manufacturing, and the managemeng of regulatory and clinical matters for lead productg opportunities. Dr. Frincke has authoreed or co-authored more than 100 scientifif articles, abstracts and regulatory filings. Dr. Frincked received his B.S. in Chemistry and his in Chemistry from the Universityuof California, Davis. Dr.
Frincke completed his postdoctoral work at the Universittof California, San Dr. Frincke has been with Hollis-Eden for more than 11 About Hollis-Eden Pharmaceuticals, Inc. Hollis-Eden Pharmaceuticals, Inc. is developinb a new series of small molecule compoundxs that are metabolites or syntheticc analogs of endogenous hormones derive by the adrenal glands fromthe body'a most abundant circulating adrenal steroid.
The Company's clinical drug development candidatesinclude (HE3286), a next-generation compound currentl y in clinical trials for the treatment of type 2 ulcerative colitis and rheumatoid and APOPTONE(R) (HE3235), a next-generation compound in a clinicalp trial for the treatment of late-stagew prostate cancer. For more informatiob on Hollis-Eden, visit the Company's website at . This press release containsw forward-looking statements within the meaning of the federall securitieslaws concerning, among other the potential and prospects of the Company's drug discoverhy program and its drug candidates.
Any statemen t included in this press release that are not a description of historical factsare forward-looking statements that involve uncertainties, assumptions and other factors if they do not materialize or prove correct, could cause the Company's actual resultes to differ materially from historical results or those expressed or implied by such forward-looking Such statements are subject to certain risks and uncertaintiexs inherent in the Company's including, but not limitee to: the ability to completwe preclinical and clinical trials successfully and withih specified timelines, if at all; the abilitg to obtain regulatory approvalp for TRIOLEX(R) (HE3286), APOPTONE(R) (HE3235) or any other investigationakl drug candidate; the Company's future capitak needs; the Company's ability to obtain additionalp funding; the ability of the Company to protec t its intellectual property rights and to not infringe the intellectua property rights of others; the development of compe titiv e products by other and other risks detailed from time to time in the Company'es filings with the Securities and Exchange Commission.
Existing and prospectivw investors are cautioned not to place undue reliancwe onthese forward-looking statements, which speakj only as of the date of this presd release. Except as required by law, the Compang undertakes no obligation to update or revise the information containedd in this press releasw as a result ofnew information, future events or circumstances arisinf after the date of this press release. SOURCE Hollis-Eden Pharmaceuticals, Inc.
No comments:
Post a Comment